Exact Mass: 467.1791
Exact Mass Matches: 467.1791
Found 471 metabolites which its exact mass value is equals to given mass value 467.1791
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
O-Ethyl-4-[(2',3',4'-tri-O-acetyl-alpha-L-rhamnosyloxy)benzyl]carbamate
O-Ethyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnosyloxy)benzyl]carbamate is a fully acetylated carbamate glycoside. It has been isolated from the leaves of Moringa oleifera (horseradish tree). It is found in fats and oils, herbs and spices, and green vegetables.
N-Desmethylrosuvastatin
N-Desmethylrosuvastatin is a metabolite of rosuvastatin. Rosuvastatin (marketed by AstraZeneca as Crestor) is a member of the drug class of statins, used to treat high cholesterol and related conditions, and to prevent cardiovascular disease. It was developed by Shionogi. (Wikipedia)
4-Hydroxytamoxifen sulfate
4-Hydroxytamoxifen sulfate is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)
(2s,4s,5r,6r)-5-Acetamido-4-hydroxy-2-(4-methyl-2-oxo-chromen-7-yl)oxy-6-[(2r)-1,2,3-trihydroxypropyl]tetrahydropyran-2-carboxylic acid
10-EdAM
Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone
Methyl 5-[(E)-1-(3,7-dimethyl-2-oxo-1,3-benzoxazol-5-yl)-6-methoxy-6-oxohex-1-enyl]-2-methoxy-3-methylbenzoate
N-[1'-(6-Cyano-1,2,3,4-tetrahydronaphthalen-2-yl)-4-hydroxyspiro[3,4-dihydrochromene-2,4'-piperidine]-6-yl]methanesulfonamide
Firuglipel
Antibiotic K 252a
Pelitinib
3-[4-(1-benzyl-3,6-dihydro-2H-pyridin-4-yl)-3,5-difluorophenyl]-5-(1,2-oxazol-3-yloxymethyl)-1,3-oxazolidin-2-one
k-252a
A organic heterooctacyclic compound that is a potent inhibitor of protein kinase C and is isolated from Nocardiopsis sp K-252a C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D004791 - Enzyme Inhibitors K-252a, a staurosporine analog, inhibits protein kinase, with IC50 values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca2+/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively[1][2]. K-252a is a potent inhibitor (IC50 of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene[3].
YM201636
Ala Cys Phe Lys
Ala Cys Phe Gln
Ala Cys Lys Phe
Ala Cys Gln Phe
Ala Phe Cys Lys
Ala Phe Cys Gln
Ala Phe Lys Cys
Ala Phe Gln Cys
Ala Lys Cys Phe
Ala Lys Phe Cys
Ala Asn Thr Tyr
Ala Asn Tyr Thr
Ala Gln Cys Phe
Ala Gln Phe Cys
Ala Gln Ser Tyr
Ala Gln Tyr Ser
Ala Ser Gln Tyr
Ala Ser Tyr Gln
Ala Thr Asn Tyr
Ala Thr Tyr Asn
Ala Tyr Asn Thr
Ala Tyr Gln Ser
Ala Tyr Ser Gln
Ala Tyr Thr Asn
Cys Ala Phe Lys
Cys Ala Phe Gln
Cys Ala Lys Phe
Cys Ala Gln Phe
Cys Cys Asp Lys
Cys Cys Gly Trp
Cys Cys Lys Asp
Cys Cys Arg Ser
Cys Cys Ser Arg
Cys Cys Trp Gly
Cys Asp Cys Lys
Cys Asp Lys Cys
Cys Phe Ala Lys
Cys Phe Ala Gln
Cys Phe Lys Ala
Cys Phe Gln Ala
Cys Gly Cys Trp
Cys Gly Trp Cys
Cys Lys Ala Phe
Cys Lys Cys Asp
Cys Lys Asp Cys
Cys Lys Phe Ala
Cys Lys Met Ser
Cys Lys Ser Met
Cys Met Lys Ser
Cys Met Asn Thr
Cys Met Gln Ser
Cys Met Ser Lys
Cys Met Ser Gln
Cys Met Thr Asn
Cys Asn Met Thr
Cys Asn Thr Met
Cys Gln Ala Phe
Cys Gln Phe Ala
Cys Gln Met Ser
Cys Gln Ser Met
Cys Arg Cys Ser
Cys Arg Ser Cys
Cys Ser Cys Arg
Cys Ser Lys Met
Cys Ser Met Lys
Cys Ser Met Gln
Cys Ser Gln Met
Cys Ser Arg Cys
Cys Thr Met Asn
Cys Thr Asn Met
Cys Trp Cys Gly
Cys Trp Gly Cys
Asp Cys Cys Lys
Asp Cys Lys Cys
Asp Gly Asn Tyr
Asp Gly Tyr Asn
Asp Lys Cys Cys
Asp Asn Gly Tyr
Asp Asn Tyr Gly
Asp Tyr Gly Asn
Asp Tyr Asn Gly
Phe Ala Cys Lys
Phe Ala Cys Gln
Phe Ala Lys Cys
Phe Ala Gln Cys
Phe Cys Ala Lys
Phe Cys Ala Gln
Phe Cys Lys Ala
Phe Cys Gln Ala
Phe Gly Met Asn
Phe Gly Asn Met
Phe Lys Ala Cys
Phe Lys Cys Ala
Phe Met Gly Asn
Phe Met Asn Gly
Phe Asn Gly Met
Phe Asn Met Gly
Phe Asn Ser Thr
Phe Asn Thr Ser
Phe Gln Ala Cys
Phe Gln Cys Ala
Phe Gln Ser Ser
Phe Ser Asn Thr
Phe Ser Gln Ser
Phe Ser Ser Gln
Phe Ser Thr Asn
Phe Thr Asn Ser
Phe Thr Ser Asn
Gly Cys Cys Trp
Gly Cys Trp Cys
Gly Asp Asn Tyr
Gly Asp Tyr Asn
Gly Phe Met Asn
Gly Phe Asn Met
Gly Met Phe Asn
Gly Met Asn Phe
Gly Asn Asp Tyr
Gly Asn Phe Met
Gly Asn Met Phe
Gly Asn Tyr Asp
Gly Gln Thr Tyr
Gly Gln Tyr Thr
Gly Thr Gln Tyr
Gly Thr Tyr Gln
Gly Trp Cys Cys
Gly Tyr Asp Asn
Gly Tyr Asn Asp
Gly Tyr Gln Thr
Gly Tyr Thr Gln
His Asn Pro Thr
His Asn Thr Pro
His Pro Asn Thr
His Pro Gln Ser
His Pro Ser Gln
His Pro Thr Asn
His Gln Pro Ser
His Gln Ser Pro
His Ser Pro Gln
His Ser Gln Pro
His Thr Asn Pro
His Thr Pro Asn
Lys Ala Cys Phe
Lys Ala Phe Cys
Lys Cys Ala Phe
Lys Cys Cys Asp
Lys Cys Asp Cys
Lys Cys Phe Ala
Lys Cys Met Ser
Lys Cys Ser Met
Lys Asp Cys Cys
Lys Phe Ala Cys
Lys Phe Cys Ala
Lys Met Cys Ser
Lys Met Ser Cys
Lys Ser Cys Met
Lys Ser Met Cys
Met Cys Lys Ser
Met Cys Asn Thr
Met Cys Gln Ser
Met Cys Ser Lys
Met Cys Ser Gln
Met Cys Thr Asn
Met Phe Gly Asn
Met Phe Asn Gly
Met Gly Phe Asn
Met Gly Asn Phe
Met Lys Cys Ser
Met Lys Ser Cys
Met Asn Cys Thr
Met Asn Phe Gly
Met Asn Gly Phe
Met Asn Thr Cys
Met Gln Cys Ser
Met Gln Ser Cys
Met Ser Cys Lys
Met Ser Cys Gln
Met Ser Lys Cys
Met Ser Gln Cys
Met Thr Cys Asn
Met Thr Asn Cys
Asn Ala Thr Tyr
Asn Ala Tyr Thr
Asn Cys Met Thr
Asn Cys Thr Met
Asn Asp Gly Tyr
Asn Asp Tyr Gly
Asn Phe Gly Met
Asn Phe Met Gly
Asn Phe Ser Thr
Asn Phe Thr Ser
Asn Gly Asp Tyr
Asn Gly Phe Met
Asn Gly Met Phe
Asn Gly Tyr Asp
Asn His Pro Thr
Asn His Thr Pro
Asn Met Cys Thr
Asn Met Phe Gly
Asn Met Gly Phe
Asn Met Thr Cys
Asn Pro His Thr
Asn Pro Thr His
Asn Ser Phe Thr
Asn Ser Thr Phe
Asn Thr Ala Tyr
Asn Thr Cys Met
Asn Thr Phe Ser
Asn Thr His Pro
Asn Thr Met Cys
Asn Thr Pro His
Asn Thr Ser Phe
Asn Thr Tyr Ala
Asn Tyr Ala Thr
Asn Tyr Asp Gly
Asn Tyr Gly Asp
Asn Tyr Thr Ala
Pro His Asn Thr
Pro His Gln Ser
Pro His Ser Gln
Pro His Thr Asn
Pro Asn His Thr
Pro Asn Thr His
Pro Gln His Ser
Pro Gln Ser His
Pro Ser His Gln
Pro Ser Gln His
Pro Thr His Asn
Pro Thr Asn His
Gln Ala Cys Phe
Gln Ala Phe Cys
Gln Ala Ser Tyr
Gln Ala Tyr Ser
Gln Cys Ala Phe
Gln Cys Phe Ala
Gln Cys Met Ser
Gln Cys Ser Met
Gln Phe Ala Cys
Gln Phe Cys Ala
Gln Phe Ser Ser
Gln Gly Thr Tyr
Gln Gly Tyr Thr
Gln His Pro Ser
Gln His Ser Pro
Gln Met Cys Ser
Gln Met Ser Cys
Gln Pro His Ser
Gln Pro Ser His
Gln Ser Ala Tyr
Gln Ser Cys Met
Gln Ser Phe Ser
Gln Ser His Pro
Gln Ser Met Cys
Gln Ser Pro His
Gln Ser Ser Phe
Gln Ser Tyr Ala
Gln Thr Gly Tyr
Gln Thr Tyr Gly
Gln Tyr Ala Ser
Gln Tyr Gly Thr
Gln Tyr Ser Ala
Gln Tyr Thr Gly
Arg Cys Cys Ser
Arg Cys Ser Cys
Arg Ser Cys Cys
Ser Ala Gln Tyr
Ser Ala Tyr Gln
Ser Cys Cys Arg
Ser Cys Lys Met
Ser Cys Met Lys
Ser Cys Met Gln
Ser Cys Gln Met
Ser Cys Arg Cys
Ser Phe Asn Thr
Ser Phe Gln Ser
Ser Phe Ser Gln
Ser Phe Thr Asn
Ser His Pro Gln
Ser His Gln Pro
Ser Lys Cys Met
Ser Lys Met Cys
Ser Met Cys Lys
Ser Met Cys Gln
Ser Met Lys Cys
Ser Met Gln Cys
Ser Asn Phe Thr
Ser Asn Thr Phe
Ser Pro His Gln
Ser Pro Gln His
Ser Gln Ala Tyr
Ser Gln Cys Met
Ser Gln Phe Ser
Ser Gln His Pro
Ser Gln Met Cys
Ser Gln Pro His
Ser Gln Ser Phe
Ser Gln Tyr Ala
Ser Arg Cys Cys
Ser Ser Phe Gln
Ser Ser Gln Phe
Ser Thr Phe Asn
Ser Thr Asn Phe
Ser Tyr Ala Gln
Ser Tyr Gln Ala
Thr Ala Asn Tyr
Thr Ala Tyr Asn
Thr Cys Met Asn
Thr Cys Asn Met
Thr Phe Asn Ser
Thr Phe Ser Asn
Thr Gly Gln Tyr
Thr Gly Tyr Gln
Thr His Asn Pro
Thr His Pro Asn
Thr Met Cys Asn
Thr Met Asn Cys
Thr Asn Ala Tyr
Thr Asn Cys Met
Thr Asn Phe Ser
Thr Asn His Pro
Thr Asn Met Cys
Thr Asn Pro His
Thr Asn Ser Phe
Thr Asn Tyr Ala
Thr Pro His Asn
Thr Pro Asn His
Thr Gln Gly Tyr
Thr Gln Tyr Gly
Thr Ser Phe Asn
Thr Ser Asn Phe
Thr Tyr Ala Asn
Thr Tyr Gly Gln
Thr Tyr Asn Ala
Thr Tyr Gln Gly
6-hydroxydoxazosin
Trp Cys Cys Gly
Trp Cys Gly Cys
Trp Gly Cys Cys
Tyr Ala Asn Thr
Tyr Ala Gln Ser
Tyr Ala Ser Gln
Tyr Ala Thr Asn
Tyr Asp Gly Asn
Tyr Asp Asn Gly
Tyr Gly Asp Asn
Tyr Gly Asn Asp
Tyr Gly Gln Thr
Tyr Gly Thr Gln
Tyr Asn Ala Thr
Tyr Asn Asp Gly
Tyr Asn Gly Asp
Tyr Asn Thr Ala
Tyr Gln Ala Ser
Tyr Gln Gly Thr
Tyr Gln Ser Ala
Tyr Gln Thr Gly
Tyr Ser Ala Gln
Tyr Ser Gln Ala
Tyr Thr Ala Asn
Tyr Thr Gly Gln
Tyr Thr Asn Ala
Tyr Thr Gln Gly
YM-201636
Bis-N-butyl phthalate
4-Acetamidophenyl-2,3,4-tri-O-acetyl-b-D-glucuronide methyl ester
Edatrexate
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2153 - Dihydrofolate Reductase Inhibitor D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists D000970 - Antineoplastic Agents
CIQ
CIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit. IC50 value: 2.7 μM (EC50, for NR2C) and 2.8 μM (EC50, NR2D) Target: NMDA receptor CIQ increases channel opening frequency of recombinant NR2Cor NR2D containing receptors by two-fold (EC50 = 2.7 and 2.8 μM, respectively), with no effect on NR2A or NR2B subtypes. CIQ does not alter the EC50 values for glutamate or glycine on channel opening. CIQ increases channel opening efficiency and enhances NMDA receptor responses. CIQ reduces associated behaviours in schizophrenia models and potentially enhances dopamine release in Parkinson's disease models.
Pelitinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors COVID info from PDB, Protein Data Bank D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Citarinostat
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D004791 - Enzyme Inhibitors > D056572 - Histone Deacetylase Inhibitors C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
1,4-Pentanediamine, N1,N1-bis(2-chloroethyl)-N4-(6-chloro-2-methoxy-9-acridinyl)-
D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D009588 - Nitrogen Mustard Compounds D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D049408 - Luminescent Agents D004396 - Coloring Agents > D005456 - Fluorescent Dyes
Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors D009676 - Noxae > D000477 - Alkylating Agents > D000590 - Amino Acid Chloromethyl Ketones
4-[(2R,5R)-3-hydroxy-5-[4-[2-(4-hydroxyphenyl)ethylamino]-4-oxobutanoyl]oxy-6-methyloxan-2-yl]oxypentanoic acid
Methyl 5-(1-(3,7-dimethyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-6-methoxy-6-oxohex-1-enyl)-2-methoxy-3-methylbenzoate
(Z)-N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
4-[[(4-methoxyphenyl)sulfonylamino]methyl]-N-[2-[methyl-(phenylmethyl)amino]ethyl]benzamide
dimethyl 1-[(4-methylphenyl)methyl]-4-(3,4,5-trimethoxyphenyl)-4H-pyridine-3,5-dicarboxylate
6-Hydroxy-1-(2-methoxyphenyl)-2-[[2-(4-morpholinyl)-2-oxoethyl]thio]-5-(phenylmethyl)-4-pyrimidinone
2-(4-chloro-3,5-dimethylphenoxy)-N-[4-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]phenyl]acetamide
5-methyl-N-[(S)-[(1S,2R)-1-methyl-2-[(2R)-1-(2-naphthalenylamino)-1-oxopropan-2-yl]cyclopropyl]-phenylmethyl]-3-isoxazolecarboxamide
N-[4-({[(4-tert-butylphenyl)carbonyl]carbamothioyl}amino)-2-methoxyphenyl]thiophene-2-carboxamide
3-[3-[(E)-[(2-hydroxy-2,2-diphenylacetyl)hydrazinylidene]methyl]-2,5-dimethylpyrrol-1-yl]benzoic acid
1-[(2-oxo-3,4-dihydro-1H-quinolin-6-yl)sulfonyl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-piperidinecarboxamide
Ethyl 5-oxo-5-[(18-phenyl-11-oxa-13,15-diazatetracyclo[8.8.0.02,7.012,17]octadeca-1(10),2,4,6,8,12,14,16-octaen-16-yl)amino]pentanoate
1-[(1R)-2-[(3-fluorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
(6R,7R,8R)-N-(2,5-difluorophenyl)-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
N-[(4-chlorophenyl)methyl]-2-[(2R,6S,8E)-4-methyl-5,12-dioxo-2-phenyl-1,4-diazacyclododec-8-en-6-yl]acetamide
2,2,2-trifluoro-N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(2R,4aR,12aS)-5-methyl-2-[2-(4-morpholinyl)-2-oxoethyl]-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]methanesulfonamide
N-[(2R,4aS,12aR)-5-methyl-2-(2-morpholin-4-yl-2-oxoethyl)-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]methanesulfonamide
N-[(2R,4aS,12aS)-5-methyl-2-[2-(4-morpholinyl)-2-oxoethyl]-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]methanesulfonamide
2,2,2-trifluoro-N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(2S,4aR,12aS)-5-methyl-2-(2-morpholin-4-yl-2-oxoethyl)-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]methanesulfonamide
N-[(2S,4aS,12aS)-5-methyl-2-(2-morpholin-4-yl-2-oxoethyl)-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]methanesulfonamide
N-[(2R,4aR,12aR)-5-methyl-2-(2-morpholin-4-yl-2-oxoethyl)-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]methanesulfonamide
(2R,3R,3aS,9bS)-3-(hydroxymethyl)-7-(3-methoxyphenyl)-6-oxo-1-(2-thiazolylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester
2,2,2-trifluoro-N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
2,2,2-trifluoro-N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(2S,4aS,12aR)-5-methyl-2-[2-(4-morpholinyl)-2-oxoethyl]-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]methanesulfonamide
1-[(1S)-2-[(3-fluorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
(6S,7R,8S)-N-(2,5-difluorophenyl)-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7R,8S)-N-(2,5-difluorophenyl)-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7S,8R)-N-(2,5-difluorophenyl)-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
2,2,2-trifluoro-N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
2,2,2-trifluoro-N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(2S,4aR,12aR)-5-methyl-2-[2-(4-morpholinyl)-2-oxoethyl]-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]methanesulfonamide
(2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-(3-methoxyphenyl)-6-oxo-1-(2-thiazolylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester
[(8R,9S,10R)-6-(benzenesulfonyl)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
(1S,5R)-3-(4-phenylphenyl)sulfonyl-7-(4-pyridin-4-ylphenyl)-3,6-diazabicyclo[3.1.1]heptane
(1R,5S)-7-[4-(3-methoxyphenyl)phenyl]-N-[4-(trifluoromethyl)phenyl]-3,6-diazabicyclo[3.1.1]heptane-6-carboxamide
(6R,7S,8S)-N-(2,5-difluorophenyl)-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8S)-N-(2,5-difluorophenyl)-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8R)-N-(2,5-difluorophenyl)-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7R,8R)-N-(2,5-difluorophenyl)-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6Z,9Z,11E,13E,15R,16S)-15-{[(2R)-2-azaniumyl-2-carboxylatoethyl]sulfanyl}-16-hydroxyicosa-6,9,11,13-tetraenedioate
5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-benzyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one
2-amino-3-[hydroxy-[2-hydroxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
4,7-DI(Para-ethoxyphenyl)-6-(para-methylphenyl)-1,2,5-thiadiazolo(3,4-C)pyridine
20-carboxyleukotriene E4(2-)
A leukotriene anion obtained by deprotonation of the three carboxy groups and protonation of the cysteinyl alpha-amino group of 20-carboxyleukotriene E4; major species at pH 7.3.
PF-06471553
PF-06471553 is a potent, selective and orally available monoacylglycerol acyltransferase 3 (MGAT3) inhibitor, with an IC50 of 92 nM.
WAY-100135 (dihydrochloride)
WAY-100135 dihydrochloride is a selective antagonist at presynaptic and postsynaptic 5-HT1A receptor, with an IC50 of 34 nM at the rat hippocampal 5-HT1A receptor. WAY-100135 dihydrochloride has potential antipsychotic properties[1][2].